- Open Access
OKlahoma Nitrone-007: novel treatment for diffuse intrinsic pontine glioma
Journal of Translational Medicine volume 18, Article number: 424 (2020)
Diffuse intrinsic pontine glioma (DIPG) is the most common brainstem cancer in childhood. This rapidly progressing brainstem glioma holds a very dismal prognosis with median survival of less than 1 year. Despite extensive research, no significant therapeutic advancements have been made to improve overall survival in DIPG patients.
Here, we used an orthotopic xenograft pediatric DIPG (HSJD-DIPG-007) mouse model to monitor the effects of anti-cancer agent, OKlahoma Nitrone-007 (OKN-007), as an inhibitor of tumor growth after 28 days of treatment. Using magnetic resonance imaging (MRI), we confirmed the previously described efficacy of LDN-193189, a known activin A receptor, type I (ACVR1) inhibitor, in decreasing tumor burden and found that OKN-007 was equally efficacious.
After 28 days of treatment, the tumor volumes were significantly decreased in OKN-007 treated mice (p < 0.01). The apparent diffusion coefficient (ADC), as a measure of tissue structural alterations, was significantly decreased in OKN-007 treated tumor-bearing mice (p < 0.0001). Histological analysis also showed a significant decrease in CD34 expression, essential for angiogenesis, of OKN-007 treated mice (p < 0.05) compared to LDN-193189 treated mice. OKN-007-treated mice also significantly decreased protein expression of the human nuclear antigen (HNA) (p < 0.001), ACVR1 (p < 0.0001), and c-MET (p < 0.05), as well as significantly increased expression of cleaved caspase 3 (p < 0.001) and histone H3 K27-trimethylation (p < 0.01), compared to untreated mouse tumors.
With the dismal prognosis and limited effective chemotherapy available for DIPG, there is significant room for continued research studies, and OKN-007 merits further exploration as a therapeutic agent.
Diffuse intrinsic pontine glioma (DIPG) is an invasive pontine tumor that affects approximately 300 children in the United States yearly  It is the most common brainstem tumor, and affected children are most commonly between the ages of 4 and 11 . DIPG holds a grim prognosis with median survival less than 1 year . Different therapeutic approaches have been attempted to target DIPG including chemotherapy (i.e. vincristine, lomustine), targeted monoclonal therapy (bevacizumab), involved field radiation therapy, chemotherapy in conjunction with radiation therapy, intraventricular chemotherapy. Despite these efforts, the clinical course and prognosis of DIPG has not changed significantly. Large clinical centers currently use involved field radiation in combination with chemotherapy, but no standard of care practices have been established at this time. The extremely poor prognosis is due to its aggressive biology, only a transient response to radiation, with ineffective response to chemotherapeutic agents delivered on its own, as DIPG has an intact blood brain barrier (BBB) . Until recently, DIPG usually has been a diagnosis made by magnetic resonance imaging (MRI) findings alone. This is a great area of change as large clinical centers are now obtaining tissue biopsy at the time of diagnosis to better unravel the true biology of DIPG. The World Health Organization 2016 classification of central nervous system tumors replaces the clinical name of DIPG to Diffuse Midline Glioma, H3 K27M-mutant. H3K27M mutant gliomas are associated with worse clinical outcome and poor treatment response compared to wild-type tumors . Approximately 80% of DIPG tumors have a histone H3 mutation, which results in the replacement of lysine 27 with methionine (K27M). This occurs in genes encoding histone H3 variant H3.3 (H3F3A) or H3.1 (HIST1H3B). H3.3-K27M increases expression of PDGFRA and Pax3. H3.1-K27M is usually a co-mutation with ACVR1 mutations, which is the second most common mutation in DIPG, with approximately 25% of cases harboring this mutation . These mutations contribute to the aggressive biology and poor treatment response. Within the last decade, DIPG has had no significant improvement in overall survival, and there is clearly a dire need for therapeutic advancements .
The goal of our research is to assess the effectiveness of OKN-007 (OKlahoma Nitrone-007; disodium 4-[(tert-butyl-imino) methyl] benzene-1,3-disulfonate N-oxide) as a therapeutic agent for a pediatric DIPG mouse model. OKN-007 has shown promise in prior studies involving pediatric glioblastoma mouse models by decreasing growth of blood vessels, which is essential for any tumor progression . G55 is a human adult glioblastoma brain tumor initiating cell (BTIC) line that is used to create xenograft glioma models. G55 glioma bearing mice had a statistically significant increase in percent survival and decreased tumor volumes in the OKN-007 treated arm compared to the untreated group . OKN-007 is novel, as it overcomes one of the barriers of systemic chemotherapy administration, which is traversing of the BBB. With the effectiveness that OKN-007 has shown as an anti-cancer agent in preclinical models, it is currently undergoing clinical trial assessment as an investigational drug for recurrent adult glioblastomas, as well as newly diagnosed patients when combined with temozolomide [7,8,9]. OKN-OO7 has both anti-inflammatory and proapoptotic features. Immunohistochemistry (IHC) has shown the ability of OKN-007 to decrease cell proliferation by inhibiting glucose transporter 1 (GLUT-1), decrease angiogenesis measured by levels of CD-31 (an endothelial marker to assess microvascular density), decrease the expression of hypoxia inducible factor 1 α (HIF-1α) with reduced hypoxia (or increased oxygenation), and by increasing apoptosis (cleaved caspase-3) compared to untreated controls . In human liver cancer cells, OKN-007 was noted to have an anti-tumor effect by suppression of both the transforming growth factor β1 (TGFβ1)/SMAD and Hedgehog/GLII signaling pathway by inhibiting sulfatase 2 (SULF2) enzyme activity . SULF2 functions as an oncoprotein in hepatocellular carcinoma and treatment with OKN-007 significantly decreased SULF2 activity, which is associated with PDGFRα expression. OKN-007 treated F98 gliomas had substantially decreased TGFB1 protein levels, resulting in TGFB1 inhibition as the upstream regulator, and 57 downregulated genes within this pathway . Molecular-targeted MRI probes were also used to show that OKN-007 can reduce protein expression of vascular endothelial growth factor receptor 2 (VEGFR2) and reduce free radical levels [11, 12]. Clearly, OKN-007 has antitumor effects against preclinical models of glioblastoma, and liver cancers, and it is worthwhile assessing if similar effects can be seen for a fatal diagnosis such as DIPG. In addition to OKN-007, we also evaluated the efficacy of a known ACVR1 inhibitor, LDN-193189. This agent was tested in a DIPG preclinical mouse model and demonstrated prolonged survival in treated mice compared to untreated, with immunohistochemistry confirming less human nuclear antigen positivity in treated mice .
We used a previously described in vivo DIPG model using post-mortem patient-derived neurospheres, HSJD-DIPG-007 [13, 14]. This specific cell line was used because it harbors both the H3 K27M and ACVR1 mutation, creating the most aggressive pre-clinical model to assess the efficacy of OKN-007.
MRI assessment is helpful in both preclinical and clinical settings to diagnose and follow response to treatment. Here we describe the MRI characterization of this orthotopic xenograft pediatric DIPG mouse (HSJD-DIPG-007 patient-derived neurospheres) model and the effects of OKN-007 and LDN-193189 to inhibit in vivo pediatric DIPG tumor growth (Figs. 1 and 2). We used conventional T2 scans to identify surgical coordinates, and fluid attenuated inversion recovery (FLAIR) imaging was used to measure tumor volumes for morphological assessment. Gadolinium contrast enhanced images were performed to assure the mice had an intact BBB prior to treatment initiation. Advanced MRI techniques such as diffusion-weighted imaging (DWI) on day 57, after 28 days of treatment, helped characterize water mobility in relation to tumor cellularity and tissue microstructure (Fig. 3). To the best of our knowledge, this study is the first report with MRI characterization as early as 2 weeks post-implantation of an orthotopic xenograft murine model of pediatric DIPG, and the assessment of treatment response using morphological imaging after treatment with OKN-007 and LDN-193189. For this specific study, we did not perform survival analysis because we wanted to compare tumor volumes in untreated, OKN-007, and LDN-193189 treated mice after an equivalent length of treatment.
We hypothesize that mice treated with OKN-007 and LDN-193189 will have decreased final tumor volume compared to the untreated group. The treatment groups included the control group (untreated), OKN-007 treated, and LDN-193189 treated. Therapeutic agents, such as OKN-007 and LDN-193189, were administered at day 28 after surgical implantation of tumor cells. All therapeutic agents were given daily for 28 days, and on day 57, the mice were terminated for immunohistochemistry. With the dismal prognosis and limited effective chemotherapy available for DIPG, there is significant room for continued research studies to help clinicians better understand and treat pediatric DIPG patients. We hope that through our studies in mice, we are able to create hope for children with this devastating disease.
Brain tumor specimen
For the pediatric cells, there was an Institutional Review Board-approved protocol M-1608 from the Hospital Sant Joan de Deu Barcelona. Primary pediatric DIPG cells (HSJD-DIPG-007) were derived from autopsy of a 6-year-old female and were transferred as neurospheres, exponentially growing in suspension in tumorsphere media (TSM) supplemented with corresponding growth factors [15, 16], and checked for mycoplasma contamination.
Mouse DIPG model
For the animal studies, the Oklahoma Medical Research Foundation Institutional Animal Care and Use Committee approved protocol 18–25. For the DIPG mouse model, HSJD-DIPG-007 neurospheres were implanted into the fourth ventricle of 6–8 week old, male, NOD/SCID (immunocompromised) mice as described previously [14, 15, 17, 18]. All mice were sedated with isoflurane. Each mouse was immobilized using the stereotaxic device and placed on a tooth bar to assure a level, stable field. The surgical field was sterilized using povidone–iodine antiseptic swabs and a 2 cm vertical incision was created. A 1 mm burr hole was drilled after identifying coordinates, 1.4 mm posterior to the lambda and 1.0 mm lateral to midline. A glass gas-tight sterile Hamilton syringe loaded with 5 × 105 DIPG neurospheres mixed with matrigel was suspended in 4 µl volume and further advanced 3.5 mm beneath the skull to reach the fourth ventricle. Cells were injected slowly over the course of 3 min. Following injection, sterile bone cement was applied to the skull and the skin was closed with silk 4.0 surgical sutures. Intraperitoneal buprenex was administered post-operatively for pain relief during recovery. A single dose of intraperitoneal dexamethasone 2 mg/kg was also administered post-operatively to reduce intracerebral edema.
The experimental schema is depicted in Fig. 4.
The animals were divided into three treatment groups: Untreated (UT) (n = 4), OKN-007 treated (n = 4), LDN-193189 treated (n = 5) mice. Initially, we had planned on having 5 mice in each treatment arm but unfortunately, several mice had to be terminated for neurological deficits noted a few days post-operatively. Both OKN-007 and LDN-193189 treatments were initiated at day 28 after surgery. Treatment with both LDN-193189 and OKN-007 continued daily for 28 days, and mice were terminated for histological analysis on day 58 (see Fig. 4).
OKN-007 (Ryss Laboratories, Union City, CA; 99.8% purity via HPLC) was dissolved in drinking water at a concentration of 150 mg/kg/day, and treatment bottles were changed every 3 days. The optimal concentration of OKN-007 was obtained from a 3 dose in vivo study (unpublished data) in an orthotopic, synegeic GL261 mouse glioma model. Water bottles were weighed prior to bottle changes, and the amount of OKN-007 consumed per mouse was readily determined, as each OKN-007 treated mouse was housed individually. The average consumption of OKN-007 ranged from 130–150 mg/kg/day in all treated mice.
LDN-193189 (Thomas Scientific, Swedesboro, NJ; 98% purity via HPLC) was dosed at 25 mg/kg/day and administered as daily gavage treatments. Dosing was obtained based on the Cavalho et al.  study. Plastic tubing oral gavage needles were used. Mice were anesthetized shortly with isoflurane to help decrease agitation during daily gavage treatments.
Magnetic resonance techniques
MRI scans were obtained using a 30-cm horizontal Bruker Biospin magnet operating at 7 T (T; Bruker Biospin GmbH, Karsruhe, Germany), with a S116 gradient set to perform all MRI experiments. An EPI (echo planar imaging) transceiver 1H 50 W coil with a 38.0 mm inner diameter was used for signal transmission and detection. NOD/SCID mice underwent MR imaging investigations while under anesthesia (isoflurane 1.5–2.0% and 0.8 l/min O2) and restrained in a cradle, which was inserted into the MRI scanner. All animals have their body temperature maintained at 37° C with a water bath driven heating pad placed under the animal in the MRI cradle. Respiratory rates were also monitored for the entire duration of the MRI scan. Fluid attenuated inversion recovery (FLAIR) imaging (FOV = 2.0 × 2.0 cm2, TR = 10,000 ms, TE = 37.0 ms, matrix size = 256 × 256, averages = 4, slices = 14, slice thickness = 0.7 mm) was used to calculate tumor volumes and to inspect tumor morphology. In-vivo diagnostic contrast-enhanced MRI approach with injection of gadolinium contrast via an intravenous tail-vein catheter was performed at different time intervals to assess for an intact BBB. This assessment used multi-slice spin echo T1-weighted images (TR = 1000.0 ms, TE = 14 ms, FOV = 2.50 × 2.50 cm2, averages = 2, slices = 16, matrix size = 256 × 256) attained before and 15 min after tail vein gadolinium contrast agent injection (Gd-DTPA, Magnevist, Bayer Inc., Wayne, NY, USA; 0.4 mmol/kg).
MRI scans were initially performed 2 weeks after surgical implantation of tumor cells, followed by weekly imaging until termination (see Fig. 4). During scanning procedures, physiological monitoring for respiration was conducted to assess the animal’s status. Survival of mice following therapeutic protocols were monitored routinely with MRI scans and an MRI were obtained as the last time-point when the mouse is euthanized.
Diffusion-weighted imaging (DWI) was also used to characterize the mobility of water in a clinical setting with diffuse tumor involvement. Diffusion data is also valuable in documenting cellular response to drug therapy. A coronal axial multi-slice DWI sequence covering the entire tumor was performed with the following parameters: TR = 3000 ms, TE = 32.5 ms, matrix size = 96 × 96, slice thickness = 0.75 mm. Apparent diffusion coefficient (ADC) values were acquired by placing four circular regions-of-interest (ROIs) within the tumor bed and these values were averaged, and then normalized to the contralateral normal brain.
Histology and immunohistochemistry
Four micron thick histological sections, embedded in paraffin and mounted on HistoBond®Plus slides (Statlab Medical Products, Lewisville, TX) were rehydrated and washed in Tris Buffered Saline (TBS). Rabbit antibodies for anti-Histone H3K27M (cat# 31-1175-00, 1 µg/ml, RevMAB Biosciences, San Francisco, CA), H3K27 tri-methylation (Tri-Methy-Histone H3 (LYS27) (C36B11) Rabbit mAb cat#9733, 1:200, Cell signaling Technology, Danvers, MA), ALK2/ACVR1 (cat# LS-B11761, 1:100, 5 µg/ml, LSBio, Seattle, WA), CD34 (cat# ab81289, 5 µg/ml, abcam, Cambridge, MA), Met (cat# sc-10, 1:50, 4 µg/ml, Santa Cruz Biotechnology, Santa Cruz, CA), Caspase-3 (cat# sc-7148, 1:50, 4 µg/ml, Santa Cruz Biotechnology, Santa Cruz, CA). Nuclear Antigen antibody was raised in mouse against Human (cat# LS-C277289, 1:100, LSBio, Seattle, WA). Slides were processed for Immunohistochemistry using ImmPRESS VR horse anti rabbit IgG Polymer kit (cat# MP-6401, Burlingame, CA) or M.O.M. ImmPRESS™ Peroxidase Polymer kit (cat# MP-2400, Vector Labs Inc., Burlingame, CA). Antigen retrieval (pH 6 Citrate Antigen Unmasking Solution (cat# H-3300, Vector Labs Inc., Burlingame CA) was accomplished via 20 min in a steamer followed by 30 min cooling at room temperature for all antibodies except CD34 which was ten minutes in a steamer followed by 20 min in ice cold pH 6. Sections were treated with a peroxidase blocking reagent (Bloxall, cat# SP-6000, Vector Laboratories, Inc, Burlingame, CA) to inhibit endogenous peroxidase activity, followed by 2.5% normal horse serum or mouse IgG blocking reagent to inhibit nonspecific binding. Appropriate washes were in TBS. Antibodies were applied to each section and following incubation overnight at 4 °C in a humidified chamber, sections were washed in TBS and reagents were applied according to the manufacturer’s directions. Slides were incubated with NovaRed® (Vector Laboratories, Inc., Burlingame, CA) chromogen for visualization. Counterstaining was carried out with Hematoxylin QS Nuclear Counterstain (Vector laboratories, Burlingame, CA). Appropriate positive and negative tissue controls were used.
Aperio ScanScope Image Analysis System was used to analyze all the IHCs. H3.K27M, H3.K27-trimethylation (H3.K27me3), ACVR1, and human nuclear antigen IHCs were evaluated using a Positive Pixel Count procedure with the Aperio ImageScope viewer. Although the DIPG were diffuse, five ROIs were placed in heavily stained areas along the brainstem to analyze IHC expression. ROI placement was avoided in areas of necrosis or substantial artifact. The number of positive pixels from ROIs were divided by the total number of pixels (negative and positive) in the examined area, and multiplied by 100, in order to determine the percentage of positivity.
Aperio microvessel analysis algorithm using CD34 as a marker was also utilized to determine microvascular density (MVD, number of vessels per mm2). Again, ROIs were arbitrarily selected, and the MVD was calculated for untreated, OKN-007 treated, and LDN-193189 treated groups.
Graph Pad Prism 8 was the software used for statistical analysis. Statistical significance was assigned only for p values < 0.05. For statistical analysis, ANOVA testing (one-way ANOVA, multiple comparisons) was used for both tumor volume, diffusion data, and IHC analysis to compare the differences of untreated, OKN-007 treated, and LDN-193189 treated pediatric HSJD-DIPG-007 mice. A two-tailed students t-test was used to compare CD34 expression on IHC of OKN-007 and LDN-193189 treated mice.
The experimental schema is outlined in Fig. 4. Morphological imaging using FLAIR MRI was initiated on day 14 after surgical implantation. MR imaging was continued weekly until termination. Treatment with either OKN-007 or LDN-193189 was initiated on day 28. All treatments were continued for a total of 28 days, with day 56 being the last day of treatments.
We confirmed tumor engraftment by FLAIR MR imaging as early as 14 days after surgical implantation (Fig. 5). Due to the diffuse nature of DIPG tumors, T2 MR imaging was not able to capture the entirety of the tumor and dismissed tumor involvement in the ventricular space. T2-weighted imaging was only used to confirm coordinates prior to surgical implantation of DIPG cells. All mice underwent FLAIR MR imaging to identify tumor boundaries, T1-weighted contrast imaging consistent with the presence of an intact BBB (Fig. 6), DWI, and IHC assessment. Average tumor volumes for each treatment group was assessed weekly using FLAIR imaging. By the end of the treatment plan, tumor volumes stabilized for both OKN-007 and LDN-193189 treated mice, but the untreated mice had a steady incline in tumor volumes with average final tumor burden at approximately 50 mm3 (Fig. 1). This tumor burden is significantly larger than both treatment groups that had average tumor volumes of approximately 20 mm3 at the end of treatment. Final tumor volumes on day 57 were significantly decreased in the OKN-007 treated mice (16.30 ± 5.17 mm3) compared to the untreated mice (32.09 ± 17.63 mm3), with p value 0.0013. LDN-193189 also significantly (p value 0.0006) decreased tumor volumes (14.40 ± 3.25 mm3) compared to untreated mice. There was no significant difference in final tumor volumes between the two treatment arms (Fig. 2).
The DWI on day 57, prior to termination, showed that the untreated mice had significantly higher (p value < 0.001) normalized apparent diffusion coefficient (ADC) values compared to the normalized ADC values of both treatment groups, OKN-007 and LDN-193189 (Fig. 3). ADC values were normalized by subtracting the ADC within the tumor bed from the ADC within the contralateral normal tissue. The mean normalized ADC values for untreated mice was 0.61 ± 0.42, when mean normalized ADC values was − 0.17 ± 0.21 for OKN-007 treated mice and − 0.17 ± 0.22 for LDN-193189 treated mice. Clearly, both treatment groups had a response to the anticancer therapy based on the ADC ratios compared to the untreated arm. There was no significant difference in the ADC between the two treatment arms. Therefore, OKN-007 has shown to be just as effective as LDN-193189 in decreasing tumor volume and normalizing ADC values.
IHC analysis was performed for human nuclear antigen, ACVR1 antibody, CD34, H3.K27M, H3.K27me3, cleaved caspase-3, and c-met. Cell stain positivity for anti-human nuclear antigen expression was significantly decreased in both treatment groups compared to the untreated arm (0.22 ± 0.02). This analysis showed p value of 0.0005 when comparing OKN-007 treated (0.12 ± 0.03) and untreated mice, and a p value < 0.0001 when comparing LDN-193189 treated (0.10 ± 0.03) and untreated mice (Fig. 7). There was no statistical difference between the two treatment arms. Similarly, ACVR1 expression was significantly decreased in the treatment groups compared to the untreated mice (0.95 ± 0.02), with a p value < 0.0001 when both treatment groups were compared to the untreated arm (Fig. 8). Although treatment with LDN-193189 was expected to decrease ACVR1 expression (0.42 ± 0.14) as it is a known ACVR1 inhibitor, OKN-007 also significantly reduced ACVR1 (0.41 ± 0.09). IHC analysis of H3.K27M expression was not statistically different between the untreated mice and the treatment groups, and therefore data was not presented. However, H3.K27me3 expression indicated a significant increase in positivity following OKN-007 treatment (0.22 ± 0.04) compared to untreated mice (0.13 ± 0.04; p < 0.01) (Fig. 9). IHC was also used to quantify CD34 expression, a good marker for microvascular density and measure of angiogenesis. CD34 expression was significantly decreased in the treatment groups compared to the untreated mice (0.00076 ± 0.00014), with a p value of 0.001 for OKN-007 (0.00044 ± 0.00008) vs. untreated mice and a p value of 0.0457 for LDN-193189 (0.00057 ± 0.00017) vs. untreated mice. There was also a significant decrease in CD34 expression in the OKN-007 treated mice compared to LDN-193189 treated mice, with a p value of 0.0212 (Fig. 10). IHC analysis of cleaved caspase-3 was also performed to compare the level of apoptosis in the treated vs. untreated mice. OKN-007 treated mice had significantly higher expression of cleaved caspase-3 (0.55 ± 0.11) compared to both untreated mice (0.13 ± 0.07; p value 0.0002) and LDN-193189 treated mice (0.37 ± 0.09; p value 0.0405). LDN-193189 treated mice also had more cleaved caspase-3 cell stain positivity compared to untreated mice (p value 0.008), and is a mechanism of action not previously described for this agent (Fig. 11). Lastly, c-MET expression was also evaluated by IHC as increased c-MET aids in tumor progression and proliferation. c-MET is one of many HIF-1α transcriptional targets, as well as GLUT1 (glucose transporter 1), BNIP3 (BCL2/adenovirus E1B 19 kDa protein-interacting protein 3) and erythropoietin . Untreated mice had significantly higher c-MET expression (0.24 ± 0.06) compared to both the OKN-007 treated mice (0.12 ± 0.07; p value of 0.0334) and LDN-193189 treated mice (0.09 ± 0.03; p value of 0.0084) (Fig. 12). IHC analysis has confirmed the molecular benefit of treatment with OKN-007. Treatment with OKN-007 has been equally effective to LDN-193189 in decreasing expression of human nuclear antigen, ACVR1 antibody, and c-MET. OKN-007 has the added benefit of decreasing angiogenesis by suppressing CD34 expression, and also promotes apoptosis by increasing cleaved caspase-3 expression compared to LDN-193189 treated mice. Our data using OKN-007 is promising and future studies in vivo may further substantiate its use to prevent DIPG tumor angiogenesis and progression.
DIPG is an aggressive and infiltrative pontine tumor that carries a grim prognosis, accounting for the majority of deaths secondary to pediatric brain tumors . Considering that radiation therapy has only shown palliative benefits and no significant improvement has been noted with the addition of adjuvant chemotherapy, there is significant room for therapeutic advancements to treat pediatric DIPG [2, 21].
Magnetic resonance imaging
Historically, patients with DIPG were diagnosed with clinical symptoms and MRI findings alone. Diagnosis by biopsy findings is novel and prevalent in only large clinical centers [2, 22]. Nonetheless, MR imaging continues to be vital for diagnosis and follow-up of therapeutic response. We describe the first pre-clinical DIPG mouse model with serial assessment of tumor growth from 2 weeks post-surgical implantation to 57 days post-implantation to evaluate tumor growth/regression with therapeutic agents. Prior pre-clinical DIPG mouse models used bioluminescence and only characterized DIPG tumors in mice by MRI 78 days after implantation .
FLAIR MR imaging demonstrated tumor growth as early as 2 weeks post-implantation and is conventionally the MR imaging modality of choice in clinical settings. T2-weighted morphological imaging had been used for previous glioma models to measure tumor volumes; however, DIPG created more diffuse tumors with unclear boundaries and tumors also invade the ventricular space [6, 11]. Tumors within the ventricular space cannot be recognized using T2-weighted imaging as cerebrospinal fluid (CSF) has higher intensity signaling. FLAIR MR imaging offers the advantage of suppressing the signal intensity of CSF fluid and accentuating periventricular lesions . The use of FLAIR imaging has assisted us in identifying tumor boundaries within the pontine region as well as metastatic sites. Literature suggests that one-third of DIPG patients have leptomeningeal spread of their tumor . We were able to identify frontal lobe involvement of the DIPG tumors in a few mice using FLAIR imaging.
Another valuable imaging tool is diffusion weighted imaging (DWI) which uses the movement of water molecules to produce contrast in MR images. DIPG tumors are infiltrative and diffuse in nature, resulting in defective cell membranes and more inflammation, therefore resulting in the increased motion of water molecules extracellularly . This is different from what would be expected in solid tumors with increased cellularity and movement restriction of water molecules. Within DIPG, there are prognostically variable subsets that may be identified using apparent diffusion coefficient (ADC) values derived from DWI. A low ADC value (< 1300 × 10–6 mm2/s) was shown to have median survival of 3 months with tumor tissue consistent with high-grade histology. On the contrary, higher ADC values (> 1300 × 10–6 mm2/s) are associated with median survival of 13 months and low-grade histology with H3.1 K27M mutation . The HSJD-DIPG-007 patient-derived neurospheres that we used to create a preclinical DIPG mouse model were found to have mean ADC value of 611 × 10–6 mm2/s in the untreated group. This is consistent with the study that shows high-grade histology DIPG tumors having a lower ADC value, as the HSJD-DIPG-007 neurospheres have both the H3.3 K27M mutation and the ACVR1 mutation [18, 27].
DWI can also be used to monitor treatment response. After 28 days of treatment with both OKN-007 and LDN-193189, the normalized ADC values were significantly lower (p value < 0.0001) than the untreated arm. Although there was no significant difference between the two treatment arms, there was notable treatment response using both these agents. Lower ADC values in response to treatment suggests that both OKN-007 and LDN-193189 helped create an environment with less inflammation, fewer DIPG cells, and more normal brain cells with intact cell membranes.
It is likely that advanced disease, which is the case when most patients present with symptoms, results in partial disruption of the BBB especially at the microscopic level. When creating a DIPG model, we wanted to assure that the BBB was intact prior to initiating treatment, as would be the case on early identification of the disease, and this characteristic is one of the major challenges of DIPG treatment. We performed T1-weighted MR imaging before and after injection of gadolinium contrast via tail vein on day 28, prior to treatment initiation. T1-weighted images pre-contrast, followed by 5, 10, 15, and 20 min post-contrast showed no significant difference in signal intensity, consistent with an intact BBB. Our study first confirmed tumor engraftment by FLAIR imaging and then assured that the mice had a relatively intact BBB at day 28, prior to treatment initiation.
Radiotherapy is routinely used to treat DIPG, but unfortunately is palliative in nature. Prior studies have not demonstrated any survival benefit with the use of adjuvant chemotherapy versus radiation therapy alone [19, 21]. The ineffective response to chemotherapeutic agents alone is likely due to the intact BBB seen in DIPG . This is a significant challenge in therapeutic development and the primary reason we chose to treat DIPG mouse models with OKN-007. OKN-007 is a small molecule that crosses the BBB. Coutinho de Souza et al. describes the high performance liquid chromatography-derived brain tissue levels of OKN-007 treated rats and demonstrated that OKN-007 was taken up by both normal brain and tumor tissue, equally, following oral administration of OKN-007 . This data identifies a true strength of OKN-007 to be used alone and possibly also with adjuvant chemotherapy.
The potential of OKN-007 as an anti-cancer agent is due to its ability to decrease cell proliferation and angiogenesis [9, 29]. OKN-007 decreases angiogenesis by inhibition of both HIF-1 protein expression and vascular endothelial growth factor receptor 2 (VEGFR2) protein expression [9, 12]. Our lab has also previously identified the ability of OKN-007 to increase apoptosis . Our group also previously assessed tumor rebound in a rat C6 glioma model, which indicated that OKN-007-treated tumors did not return for over 60 days, after a 10 day treatment period . There are continued efforts to understand the primary mechanism of action of OKN-007, but its antiangiogenic and pro-apoptotic properties render it a valuable therapeutic agent for DIPG.
In addition to OKN-007, we also evaluated the efficacy of LDN-193189 for the treatment of pediatric DIPG. LDN-193189 is a small molecule derived from dorsomorphin, an inhibitor of the BMP pathway. It has been effective in decreasing cellular viability in multiple human cancer cell lines including glioblastoma, breast, lung, pancreatic, cervical, and prostate cancers . Unfortunately, despite its potent and selective inhibition of the BMP pathway, it is a multi-kinase inhibitor with low specificity as it inhibits a wide range of receptors and intracellular kinases. When tested against a panel of protein kinases, even at the lowest concentration of 0.1 µM of LDN-193189, it potently inhibited RIPK2, FGF-R1, NUAK1, MINK1, GCK, VEG-FR, MAPK8, AKT. It is likely that LDN-193189 may also inhibit other kinases not yet evaluated . Therefore, LDN-193189 is likely not an ideal molecule for DIPG treatment due to the high side effect profile expected with potent inhibition of numerous protein kinase pathways. Prior studies using LDN-193189 also reported weight loss as a side effect .
This study revealed the beneficial effects of OKN-007 in a preclinical mouse model of DIPG using both MRI characteristics and immunohistochemistry. Treatment with both OKN-007 and LDN-193189 significantly decreased tumor volumes and ADC values compared to the untreated group. Our study confirmed the pre-clinical benefits of LDN-193189, as previously reported. A high side-effect profile is expected as LDN-193189 is a multi-kinase inhibitor [30, 31]. The preclinical effects of OKN-007 on decreasing tumor volume in this xenograft DIPG model with a favorable safety profile, as previously reported in human stroke trials, is promising . Not only has OKN-007 shown preclinical efficacy against liver cancer, colon cancer and brain tumors such as glioblastoma, but it has clear potential as a therapeutic agent against pediatric DIPG [23, 33, 34]. OKN-007 would be a promising treatment to consider in combination with involved field radiation to potentiate the effects of radiation. The safety profile of OKN-007 is potentially higher than chemotherapeutic agents that are used in conjunction with involved field radiation.
This study focused on treatment effects comparing a similar time-frame for all treatment groups. A survival study will be incorporated in future studies.
IHC was also used to confirm cellular response to treatment. Treatment groups displayed a significant decrease in human nuclear antigen, ACVR1, CD34, and c-MET expression compared to the untreated mice. We had expected a decrease in ACVR1 expression in LDN-193189 treated mice as this is its sole mechanism of action, but we were pleased to see similar protein suppression in OKN-007 treated mice. OKN-007 treated mice also had significantly decreased CD34 expression compared to both the untreated and LDN-193189 treated mice, making this a promising therapeutic anti-cancer agent. Unexpectedly, we also found that OKN-007 increased H3.K27me3 levels, whereas LDN-193189 did not, compared to untreated tumors. Huang et al.  previously indicated decreased H3.K27me3 in H3.K27M mutant tumors, compared to wild-type, and that loss of H3.K27me3 is associated with poorer overall survival, as well as a greater likelihood of disease progression in DIPG patients. CD34 is a marker of microvascular density and angiogenesis, which is vital for tumor progression. Increased CD34 expression has been associated with new blood vessel growth and has been found in high-grade gliomas [36, 37]. OKN-007 favorably decreased expression of CD34, and may be considered a useful targeted therapy to improve overall prognosis. Along with common mutations such as ACVR1 and H3 K27M found in DIPG, 50% of DIPG cases harbor gain of function processes that stimulate tyrosine kinase receptors to trigger further tumor progression . Increased c-MET, a known hepatocyte growth factor receptor, is a similar component found in DIPG that we tested using IHC. As expected, c-MET expression was higher in untreated mice, while both treatment arms appropriately decreased levels of c-MET.
Cleaved caspase-3 is often used to evaluate the presence of apoptosis. Decreased caspase-3 activation usually signifies less apoptosis and unopposed cell proliferation, which promotes further tumor growth . Increased cleaved caspase-3 expression shifts the balance of apoptosis vs. cell proliferation to favor more apoptosis, and therefore inhibit tumor growth . Our results show that both treatment arms had higher expression of cleaved caspase-3 compared to the untreated arm. OKN-007 had a significantly higher level of apoptosis even compared to LDN-193189 treated mice and should be considered a therapeutic agent by itself.
With the dismal prognosis and limited effective chemotherapy available for DIPG, there is significant room for continued research studies and OKN-007 merits further exploration as a therapeutic agent. We particularly found that this agent, which readily crosses the BBB, can significantly decrease tumor volumes, ADC values, MVD, and HNA, c-MET and ACVR1 protein expressions, compared to untreated tumors, as well as significantly increase apoptosis. In addition, OKN-007 was able to perform better than an ACVR1 inhibitor in reducing MVD, and increasing apoptosis or H3.K27me3.
Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
Activin A receptor, type I
Apparent diffusion coefficient
Blood brain barrier
Diffuse intrinsic pontine glioma
Fluid attenuated inversion recovery
Glucose transporter 1
Hypoxia inducible factor 1 α
Human nuclear antigen
Magnetic resonance imaging
Transforming growth factor β1
Vascular endothelial growth factor receptor 2
Bondy ML, Scheurer ME, Malmer B, Barnholtz-Sloan JS, Davis FG, Il’Yasova D, et al. Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer. 2008;113(S7):1953–68.
Schroeder KM, Hoeman CM, Becher OJ. Children are not just little adults: recent advances in understanding of diffuse intrinsic pontine glioma biology. Pediatr Res. 2014;75(1–2):205–9.
Castel D, Philippe C, Calmon R, Le Dret L, Truffaux N, Boddaert N, et al. Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol. 2015;130(6):815–27.
Louis DN, Perry A, Reifenberger G, Von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–20.
Carvalho D, Taylor KR, Olaciregui NG, Molinari V, Clarke M, Mackay A, et al. ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma. Commun Biol. 2019;2:156.
Coutinho de Souza P, Mallory S, Smith N, Saunders D, Li X-N, McNall-Knapp RY, et al. Inhibition of pediatric glioblastoma tumor growth by the anti-cancer agent OKN-007 in orthotopic mouse xenografts. PLoS ONE. 2015;10(8):e0134276.
Towner RA, Smith N, Saunders D, Brown CA, Cai X, Ziegler J, et al. OKN-007 increases temozolomide (TMZ) sensitivity and suppresses TMZ-resistant glioblastoma (GBM) tumor growth. Transl Oncol. 2019;12(2):320–35.
Garteiser P, Doblas S, Watanabe Y, Saunders D, Hoyle J, Lerner M, et al. Multiparametric assessment of the anti-glioma properties of OKN007 by magnetic resonance imaging. J Magn Imaging. 2010;31(4):796–806.
Towner RA, Gillespie DL, Schwager A, Saunders DG, Smith N, Njoku CE, et al. Regression of glioma tumor growth in F98 and U87 rat glioma models by the Nitrone OKN-007. Neuro Oncology. 2013;15(3):330–40.
Zheng X, Gai X, Han S, Moser CD, Hu C, Shire AM, et al. The human sulfatase 2 inhibitor 2, 4-disulfonylphenyl-tert-butylnitrone (OKN-007) has an antitumor effect in hepatocellular carcinoma mediated via suppression of TGFB1/SMAD2 and Hedgehog/GLI1 signaling. Genes Chromosomes Cancer. 2013;52(3):225–36.
Coutinho de Souza P, Smith N, Atolagbe O, Ziegler J, Njoku C, Lerner M, et al. OKN-007 decreases free radical levels in a preclinical F98 rat glioma model. Free Radic Biol Med. 2015;87:157–68.
de Souza PC, Smith N, Pody R, He T, Njoku C, Silasi-Mansat R, et al. OKN-007 decreases VEGFR-2 levels in a preclinical GL261 mouse glioma model. Am J Nucl Med Mol Imaging. 2015;5(4):363.
Taylor KR, Mackay A, Truffaux N, Butterfield YS, Morozova O, Philippe C, et al. Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat Genet. 2014;46(5):457–61.
Vinci M, Burford A, Molinari V, Kessler K, Popov S, Clarke M, et al. Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells. Nat Med. 2018;24(8):1204–15.
Jansen MH, Lagerweij T, Sewing AC, Vugts DJ, van Vuurden DG, Molthoff CF, et al. Bevacizumab targeting diffuse intrinsic pontine glioma: results of 89Zr-bevacizumab PET imaging in brain tumor models. Mol Cancer Ther. 2016;15(9):2166–74.
Meel MH, Metselaar DS, Waranecki P, Kaspers GJ, Hulleman EJM. An efficient method for the transduction of primary pediatric glioma neurospheres. MethodsX. 2018;5:173–83.
Misuraca KL, Cordero FJ, Becher OJ. Pre-clinical models of diffuse intrinsic pontine glioma. Front Oncol. 2015;5:172.
Hennika T, Hu G, Olaciregui NG, Barton KL, Ehteda A, Chitranjan A, et al. Pre-clinical study of panobinostat in xenograft and genetically engineered murine diffuse intrinsic pontine glioma models. PLoS ONE. 2017;12(1):e0169485.
Rodriguez-Hernandez MA, de la Cruz-Ojeda P, Lopez-Grueso MJ, Navarro-Villaran E, Requejo-Aguilar R, Castejon-Vega B, et al. Integrated molecular signaling involving mitochondrial dysfunction and alteration of cell metabolism induced by tyrosine kinase inhibitors in cancer. Redox Biol. 2020;36:101510.
Jansen M, Van Vuurden D, Vandertop W, Kaspers GJ. Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology. Cancer Treat Rev. 2012;38(1):27–35.
Hargrave D, Bartels U, Bouffet EJT. Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol. 2006;7(3):241–8.
Xu C, Liu X, Geng Y, Bai Q, Pan C, Sun Y, et al. Patient-derived DIPG cells preserve stem-like characteristics and generate orthotopic tumors. Oncotarget. 2017;8(44):76644–55.
Soltaninejad M, Yang G, Lambrou T, Allinson N, Jones TL, Barrick TR, et al. Automated brain tumour detection and segmentation using superpixel-based extremely randomized trees in FLAIR MRI. Int J Comput Assist Radiol Surg. 2017;12(2):183–203.
Buczkowicz P, Bartels U, Bouffet E, Becher O, Hawkins CJ. Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications. Acta Neuropathol. 2014;128(4):573–81.
Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. Am J Roentgenol. 2007;188(6):1622–35.
Lober RM, Cho YJ, Tang Y, Barnes PD, Edwards MS, Vogel H, et al. Diffusion-weighted MRI derived apparent diffusion coefficient identifies prognostically distinct subgroups of pediatric diffuse intrinsic pontine glioma. J Neuro-Oncol. 2014;117(1):175–82.
Cordero FJ, Huang Z, Grenier C, He X, Hu G, McLendon RE, et al. Histone H3 3K27M represses p16 to accelerate gliomagenesis in a murine model of DIPG. Mol Cancer Res. 2017;15(9):1243–54.
Mathew RK, Rutka JT. Diffuse intrinsic pontine glioma : clinical features, molecular genetics, and novel targeted therapeutics. J Korean Neurosurg Soc. 2018;61(3):343–51.
de Souza PC, Balasubramanian K, Njoku C, Smith N, Gillespie DL, Schwager A, et al. OKN-007 decreases tumor necrosis and tumor cell proliferation and increases apoptosis in a preclinical F98 rat glioma model. J Magn Reson Imaging. 2015;42(6):1582–91.
Ali JL, Lagasse BJ, Minuk AJ, Love AJ, Moraya AI, Lam L, et al. Differential cellular responses induced by dorsomorphin and LDN-193189 in chemotherapy-sensitive and chemotherapy-resistant human epithelial ovarian cancer cells. Int J Cancer. 2015;136(5):E455–69.
Vogt J, Traynor R, Sapkota GP. The specificities of small molecule inhibitors of the TGFss and BMP pathways. Cell Signal. 2011;23(11):1831–42.
Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, et al. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med. 2007;357(6):562–71.
Floyd R, Chandru KH, He T, Towner RA. Anti-cancer activity of nitrones and observations on mechanism of action. Anticancer Agents Med Chem. 2011;11(4):373–9.
Yoon S, Lee E-J, Choi J-H, Chung T, Im J-Y, Bae M-H, et al. Recapitulation of pharmacogenomic data reveals that invalidation of SULF2 enhance sorafenib susceptibility in liver cancer. Oncogene. 2018;37:4443–54.
Huang T, Garcia R, Qi J, Lulla R, Horbinski C, Behdad A, et al. Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes. Oncotarget. 2018;9(98):37112–24.
Kong X, Guan J, Ma W, Li Y, Xing B, Yang Y, et al. CD34 over-expression is associated with gliomas’ higher WHO grade. Medicine (Baltimore). 2016;95(7):e2830.
Rahmah NN, Sakai K, Sano K, Hongo KJ. Expression of RECK in endothelial cells of glioma: comparison with CD34 and VEGF expressions. J Neurooncol. 2012;107(3):559–64.
Kobayashi T, Masumoto J, Tada T, Nomiyama T, Hongo K, Nakayama JJ. Prognostic significance of the immunohistochemical staining of cleaved caspase-3, an activated form of caspase-3, in gliomas. Clin Cancer Res. 2007;13(13):3868–74.
Kondo S, Tanaka Y, Kondo Y, Ishizaka Y, Hitomi M, Haqqi T, et al. Retroviral transfer of CPP32β gene into malignant gliomas in vitro and in vivo. Cancer Res. 1998;58(5):962–7.
The Oklahoma Medical Research Foundation, Oblato, Inc., and the Children’s Hospital Foundation Fellows Research Grant provided funding, as well as the National Institutes of Health (1S10OD023508 to RAT; P30 CA225520 to KMF; and P20 GM103639 to KMF).
Ethics approval and consent to participate
Human cells used in this study were obtained under a protocol (M-1608) approved by the Institutional Review Board (IRB) at Hospital Sant Joan de Déu (Barcelona, Spain). Acquisition of human tissue samples were obtained after signed informed consent from legal guardians. The Institutional Animal Care and Use Committee (IACUC) of the Oklahoma Medical Research Foundation approved the animal protocol [18,19,20,21,22,23,24,25].
Consent for publication
RAT holds patents for OKN-007 as a treatment for gliomas. The remaining authors have declared no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Thomas, L., Smith, N., Saunders, D. et al. OKlahoma Nitrone-007: novel treatment for diffuse intrinsic pontine glioma. J Transl Med 18, 424 (2020). https://doi.org/10.1186/s12967-020-02593-5
- Diffuse intrinsic pontine glioma (DIPG)
- ACVR1 mutation
- Patient-derived xenograft (PDX)
- Magnetic resonance imaging (MRI)
- Diffusion-weighted imaging (DWI)
- Microvessel density (MVD)
- H3K27 trimethylation